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We here describe a novel method for MYD88L265P mutation detec-tion and minimal residual disease monitoring in Waldenströmmacroglobulinemia, by droplet digital polymerase chain reac-
tion, in bone marrow and peripheral blood cells, as well as in circulating
cell-free DNA. Our method shows a sensitivity of 5.00x10-5, which is far
superior to the widely used allele-specific polymerase chain reaction
(1.00x10-3). Overall, 291 unsorted samples from 148 patients (133 with
Waldenström macroglobulinemia, 11 with IgG lymphoplasmacytic lym-
phoma and 4 with IgM monoclonal gammopathy of undetermined sig-
nificance) were analyzed: 194 were baseline samples and 97 were follow-
up samples. One hundred and twenty-two of 128 (95.3%) bone marrow
and 47/66 (71.2%) baseline peripheral blood samples scored positive for
MYD88L265P. To investigate whether MYD88L265P detection by droplet dig-
ital polymerase chain reaction could be used for minimal residual disease
monitoring, mutation levels were compared with IGH-based minimal
residual disease analysis in 10 patients, and was found to be as informa-
tive as the classical, standardized, but not yet validated in Waldenström
macroglobulinemia, IGH-based minimal residual disease assay (r2=0.64).
Finally, MYD88L265P detection by droplet digital polymerase chain reaction
on plasma circulating tumor DNA from 60 patients showed a good cor-
relation with bone marrow findings (bone marrow median mutational
value 1.92x10-2, plasma circulating tumor DNA value: 1.4x10-2, peripheral
blood value: 1.03x10-3). This study indicates that droplet digital poly-
merase chain reaction assay of MYD88L265P is a feasible and sensitive tool
for mutation screening and minimal residual disease monitoring in
Waldenström macroglobulinemia. Both unsorted bone marrow and
peripheral blood samples can be reliably tested, as can circulating tumor
DNA, which represents an attractive, less invasive alternative to bone
marrow for MYD88L265P detection.
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ABSTRACT
Introduction
In recent years, the MYD88L265P mutation has been recur-
rently identified in Waldenström macroglobulinemia
(WM),1,2 an indolent lymphoplasmacytic lymphoma (LPL)
characterized by the accumulation in the bone marrow
(BM) of monoclonal lymphocytes, lymphoplasmacytic
cells and plasma cells, responsible for monoclonal IgM pro-
tein secretion.3 Several studies using different techniques
such as Sanger sequencing, polymerase chain reaction
(PCR) and allele-specific quantitative PCR (ASqPCR), on
CD19-sorted BM samples, found that about 90% of WM
patients carry the MYD88L265P mutation, while it is present
in 14-29% of “activated B-cell” diffuse large B-cell lym-
phomas,4,5 6-10% of marginal zone lymphomas, 3-5% of
chronic lymphocytic leukemia and is absent in multiple
myeloma and in non-IgM monoclonal gammopathies of
uncertain significance (MGUS).6–8 Therefore, MYD88L265P is
now considered a hallmark of WM and may be helpful in
the differential diagnosis from other lymphoproliferative
neoplasms with overlapping clinical features, such as mul-
tiple myeloma.9,10 Furthermore, it might represent an ideal
marker for minimal residual disease (MRD) monitoring in
a disease whose therapeutic scenario is rapidly changing,
with many newly available and highly effective drugs.11–17
Moreover, MYD88L265P has been demonstrated in CD19-
sorted BM samples from 50-80% of patients with IgM-
MGUS, an asymptomatic phase which represents a pre-
neoplastic condition, suggesting a potential role in disease
progression.6,8,18–20 BM biopsy is mandatory for the differen-
tial diagnosis between WM and IgM-MGUS, but patients
with an asymptomatic M component do not readily agree
to undergo such an invasive procedure. The availability of
accurate diagnostic tools based on the use of peripheral
blood (PB), or even urine samples, would overcome this
problem and avoid the risk of misclassification of patients.
Additionally, the current MYD88L265P ASqPCR method
lacks sensitivity (1.00x10-3) and is not, therefore, suitable
for MRD.6,21 Indeed, ASqPCR is suboptimal for testing
specimens such as unsorted BM or even PB, which con-
tains low concentrations of circulating tumor cells (espe-
cially after immunochemotherapy), or for assessing cell-
free tumor DNA (ctDNA), usually present in only very
small amounts in plasma, including cerebrospinal fluid and
pleural effusions.22,23 Recently, digital PCR has been shown
to be a powerful technique that provides improved sensi-
tivity, precision and reproducibility, overcoming some of
the pitfalls of qPCR.24,25 We here describe a newly devel-
oped, highly sensitive, droplet digital PCR (ddPCR) assay
for the identification of the MYD88L265P mutation in
patients affected by WM or LPL, suitable for screening and
MRD monitoring on BM and PB cells, as well as on cell-
free DNA. 
Methods 
Patients and samples collection 
BM, PB, plasma and urine samples were collected at baseline
and during follow up from patients affected by WM, IgM-MGUS
or IgG-secreting LPL (Online Supplementary Figure S1). Consecutive
patients were included in this study and were classified based on
the 2008 World Health Organization classification criteria.3 PB
from 40 healthy subjects and BM from 20 patients with multiple
myeloma were used as negative controls. Sample collection and
storage as well as nucleic acid extraction procedures are described
in the Online Supplementary Appendix.
All patients provided written informed consent to the use of
their biological samples for research, in accordance with
Institutional Review Board provisions and the Declaration of
Helsinki. This study was approved by the local ethics committee. 
Droplet digital polymerase chain reaction assays for
detection of the MYD88L265P mutation  
The mutation detection assay was designed as reported in
Online Supplementary Figure S2A. ddPCR was performed using the
QX100 Droplet Digital PCR system (Bio-Rad Laboratories) as
detailed in the Online Supplementary Appendix. Samples were test-
ed in triplicate and results are expressed as merge of wells. The
cut-off for defining the presence of the mutation was set based on
the highest MYD88L265P level detected within the control group and
is indicated in figures as a red dashed line. Samples with a ratio
value below the red dashed line are considered MYD88L265P wild-
type (WT). Each experiment included a no template control, a
known highly mutated positive control sample (mutation rate =
70%, mutated/WT ratio 7x10-1), previously tested by Sanger
sequencing, as reported by Treon et al.,1 and a negative control
(healthy donor or multiple myeloma gDNA). dMIQE guidelines
(Minimum Information for Publication of Quantitative Digital
PCR Experiments) for ddPCR experiments are listed in Online
Supplementary Table S1.25
Allele-specific quantitative polymerase chain reaction
assay for detection of the MYD88L265P mutation 
The sensitivity of MYD88L265P ddPCR was compared to that of
the ASqPCR assay previously described by Xu et al.6 on a standard
curve of 10-fold serial dilutions. In parallel, 100 WM samples from
the Torino series and 23 patients from the Salamanca series were
analyzed, following the strategy described by Jiménez et al.21
Additionally, MYD88L265P mutation detection by ddPCR was com-
pared to that of the qBiomarker™ Somatic Mutation Assay kit for
MYD88_85940 (Qiagen) on 15 samples from the University of Pisa.
Allele-specific quantitative polymerase chain reaction
assay for tumor-specific IGH-VDJ rearrangement 
In order to perform a comparison to the worldwide standard-
ized ASqPCR technique for immunoglobulin-VDJ rearrangement
(IGH-VDJ) MRD analysis, patient-specific IGH-VDJ was amplified
and directly sequenced26 (Online Supplementary Figure S2B). This
IGH-based MRD analysis was performed according to the Euro-
MRD guidelines.27
Statistical analysis
Associations between categorical variables were analyzed by the
Fisher exact test, while Mann-Whitney and Kruskal-Wallis tests
were used for the inference on continuous variables. Results of the
analyses of continuous variables are expressed as the median
(range); ddPCR and ASqPCR results are expressed as mutated:WT
ratio. The interrater agreement on categorical data was estimated
by computing the Fleiss kappa (k) index. All reported P-values were
estimated by the two-sided exact method with the conventional
5% significance level. Data were analyzed as of July 2017 using R
3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).28
Results
Patients and samples
Overall, 291 samples from 148 patients from the three
series were analyzed (133 WM, 1 amyloid-associated
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IgM-LPL, 10 IgG-LPL, 4 IgM-MGUS): 194 samples were
taken at baseline in active disease (128 BM, 66 PB) and 97
samples during follow up (43 BM and 54 PB). The baseline
samples were defined either “treatment-naïve” (143/194,
73.7%, 99 BM and 44 PB) or “relapsed” (51/194, 26.2%, 29
BM and 22 PB), according to previous exposure to chemo-
immunotherapy. All the follow-up samples were taken for
the purpose of studying MRD at different time points
after specific treatment. The distribution of the study pop-
ulation is summarized in Online Supplementary Figure S1,
while the patients’ main clinical features are detailed in
Table 1. 
Detection limit of droplet digital polymerase chain
reaction
The detection limit of ddPCR was determined using a
serial dilution of MYD88L265P mutated gDNA in WT DNA
at levels of 35, 3.5, 0.35, 0.035 and 0.0035%, correspon-
ding to 10500, 1050, 105, 10.5 and 1 mutated copy pres-
ent in 100 ng of gDNA (30,000 copies) which is the over-
all quantity of gDNA loaded per well. We identified the
limit of detection using a statistical method based on
binomial distribution, as previously reported.29 This
analysis indicated that we were able to detect the muta-
tion, with a good degree of confidence, when the level of
mutated copies was more than 0.035% (10 mutated
copies in 30000 WT). This value mirrored the cut-off
mutated:WT ratio we identified based on the control
group (40 healthy subjects) (Figure 1A). Additional repro-
ducibility tests confirmed that the above calculated limit
of detection and the experimentally detected cut-off,
emerging from the control group, are equally reliable
(Online Supplementary Table S2). 
MYD88L265P screening by droplet digital polymerase
chain reaction in baseline samples
Overall 142/148 (96%) patients were identified as hav-
ing the MYD88L265P mutation. We observed a 91.6% muta-
tion rate (33/36) among relapsed patients and 97.3% rate
(109/112) among treatment-naïve patients (P=0.15).
Notably, no one of the 6 MYD88L265P WT patients (4 WM
with histological BM invasion of 20%, 30%, 30% and
60%) or 2 patients with IgG LPL (with 20% and 30% his-
tological BM invasion) showed either alternative MYD88
or CXCR4 mutations, as investigated by Sanger sequenc-
ing on unselected cells.10,12,30 All BM samples from 20
patients with multiple myeloma used as negative controls
were below the limit of detection (defined as previously
described) and below the mutation cut-off ratio estab-
lished based on 40 PB samples from healthy individuals
(mutated:WT ratio <3.4x10-4) (Figure 1A). Moreover, to
confirm the specificity of our assay for mutational screen-
ing, 15 patients with mantle cell lymphoma, 10 with fol-
licular lymphoma and 10 with chronic lymphocytic
leukemia were tested for the MYD88L265P mutation. All
samples from the patients with follicular lymphoma or
mantle cell lymphoma were WT, whereas one of the 10
patients with chronic lymphocytic leukemia showed a
mutation ratio of 4.4x10-4, as already described in this dis-
ease.6
Looking at the single tissues, 95.3% (122/128) of base-
line BM and 71.2% (47/66) of PB samples scored positive
for MYD88L265P (BM median mutation burden 3.60x10-2,
range: 2.00x10-4 – 7.30 x10-1; PB median 5.00x10-3, range:
1.00x10-4 – 2.80 x10-1) (Figure 1A). Notably, among the PB
samples there was a statistically significant difference in
mutation rate between samples from relapsed patients
(median burden 4.00x10-4, range: 1.00x10-4 – 1.00x10-3) and
treatment-naïve patents (median burden 2.80x10-3, range:
2.00x10-4 – 1.00x10-2), supporting the possible negative
impact on mutation detection of previous treatment on PB
samples (P<0.0001) (Figure 1B). 
Seventy-four patients in this series had paired baseline
BM and PB samples. Overall, in this subgroup of patients,
the rate of MYD88L265P mutation detection by ddPCR was
93% (69/74) on BM and 72% (53/74) on PB samples.
Accordingly, the detection rates were higher among treat-
ment-naïve patients than among relapsed patients: 95%
(52/55) on BM and 82% (45/55) on PB versus 89% (17/19)
on BM and 42% (8/19) on PB, respectively (P=0.014). In
addition, 15 of these 74 patients (20%) showed BM-
mutated/PB-WT discordance, such discordance being
more frequent among relapsed cases than among treat-
ment-naïve cases (8/19, 42% vs. 7/55, 13%; P=0.02)
(Figure 1C).
Finally, a test of within-run reproducibility showed uni-
form results across the experiments, with an inter-assay
Standard Deviation (SD) of 1.3% for the MYD88L265P posi-
tive control and 0.01% for WT gDNA samples. 
Comparison of MYD88L265P droplet digital
polymerase chain reaction versus allele-specific 
quantitative polymerase chain reaction assays
Once the ddPCR assay had been optimized, the sensi-
tivity of the MYD88L265P ddPCR was compared to that of
ASqPCR on a standard curve of 10-fold serial dilutions
constructed with a highly MYD88L265P mutated WM sam-
ple (70%, mutated/WT ratio 7.00x10-1, diluted to 35%),
MYD88L265P mutation detection by ddPCR on BM, PB and ctDNA
haematologica | 2018; 103(6) 1031
Table 1. Patients’ clinical and biological features at baseline.
Patients’ chacteristics
Baseline samples (n= 148)
Waldenström macroglobulinemia                                     133 (89.8%)
IgG-lymphoplasmacytic lymphoma                                      10 (6.7%)
IgM-MGUS                                                                                  4 (2.8%)
IgM-LPL amyloid tumor                                                           1 (0.7%)
Sex, female                                                                                51 (34%)
Median age  (years, range)                                                  67 (24-88)
Median hemoglobin (range), g/dL                                  11.5 (7.5-16.8)
Median IgM (range), g/dL
Waldenström macroglobulinemia                                2.397 (0.233-12.5)
MGUS                                                                                 0.785 (0.492-2.252)
Median IgG (range), g/dL
IgG-lymphoplasmacytic lymphoma                             1.958 (0.916-3.447)
Median β2 microglobulin (range), mg/L                          2.62 (1-8.83)
Median bone marrow infiltration
Bone marrow biopsy                                                            40% (0-95%)
Bone marrow flow cytometry                                            12%  (0-87%)
Organomegaly
Splenomegaly                                                                            18 (12%)
Adenopathies                                                                           29 (19.5%)
LPL: lymphoplasmacytic lymphoma; MGUS: monoclonal gammopathy of undeter-
mined significance.
previously identified by Sanger sequencing.1 Whereas the
ASqPCR standard curve confirmed the reported sensitivi-
ty of 1.00x10-3 (0.25% out of 6000 WT),6 ddPCR reached a
1.5 log higher sensitivity (0.0035% out of 30000 WT) also
because of the larger amount of gDNA used in ddPCR
than in ASqPCR (100 ng vs. 20 ng) (Figure 2 and Online
Supplementary Table S2). Overall, 100 WM samples (48
BM, 52 PB, 40 baseline and 60 follow up) from 48 patients,
as well as 20 control samples (15 healthy subjects and 5
with multiple myeloma) were tested by both methods
(Online Supplementary Figure S3). An example of mutation
analysis performed by both methods on 2 patients is pre-
sented in Online Supplementary Figure S4. Of the 40 base-
line samples tested by both methods, 35 (87.5%) scored
positive and 4 (10%) scored negative for MYD88L265P by
both ddPCR and ASqPCR (with there being only one dis-
cordant ddPCR+/ASqPCR– case), while higher number of
discordances were observed among follow-up samples:
13/60 (21.7%) ddPCR+/ASqPCR–, and 11/60 (18.3%)
ddPCR–/ASqPCR+ (Online Supplementary Table S3). Indeed,
the strength of agreement was very good in the baseline
cases (Cohen κ=0.8) but poor in follow-up samples
(Cohen κ=0.2), resembling what had been previously
shown for low burden infiltrated samples.31 All control
samples scored negative by both methods (median:
ddPCR 1.75x10-4 (range 3.10x10-4 – 2.70x10-5) and ASqPCR
∆CT=10 (range ∆CT=8.4-10.7, setting ∆CT=8 as the cut-
off for negativity). 
Comparison of MYD88L265P and IGH-based digital
droplet polymerase chain reaction assays for the 
purposes of minimal residual disease detection
To investigate whether ddPCR of MYD88L265P could be
used for MRD detection, we compared it to the highly
sensitive IGH-based MRD ddPCR assay. Only patients
with available follow-up samples were screened for IGH
rearrangements. A clonal VDJ rearrangement was detect-
ed in 34/52 (65%) patients, as expected in WM.32 All these
patients scored positive for MYD88L265P by ddPCR. We,
therefore, tested 10 informative patients, at baseline and
during clinical follow up, with both techniques. Overall,
there was good concordance (r2=0.64) between the two
methods (P<0.0001) in the 23 samples (18 BM, 5 PB)
(Figure 3).
MYD88L265P digital droplet polymerase chain 
reaction on circulating tumor DNA 
In order to investigate the feasibility and the sensitivity
advantages of ddPCR-based MYD88L265P mutation detec-
tion on plasma ctDNA vs. PB gDNA, paired samples from
60 patients were analyzed. Interestingly, a higher median
MYD88L265P mutated / WT ratio was detected in plasma
ctDNA (1.4x10-2) than in PB (1.03 x10-3) (P<0.001) (Online
Supplementary Figure S5), while no statistically significant
difference was observed between ctDNA and BM samples
from 32 patients (1.92x10-2 vs. 1.4x10-2; P=0.2). Figure 4
shows the matches among BM, plasma and PB MYD88L265P
D. Drandi et al.
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Figure 1. MYD88L265P mutation at baseline is lower in peripheral blood (PB)
than in bone marrow (BM). (A) Waldenström macroglobulinemia (WM) patients
show statistically significant differences in mutated/wild-type ratio (MUT/WT)
between BM and PB samples (P<0.0001). The control group of healthy subjects
and multiple myeloma (MM) patients show MUT/WT ratios below the limit of
detection. The dashed red line shows the cut-off for mutational status. Symbols
below the red line represent MYD88WT samples. (B) MUT/WT ratio differences
between relapsed (RE) and Naïve to Treatment (NT) patients, at baseline, is
higher in PB than in BM samples. (C) MYD88L265P MUT/WT ratio at baseline in
pared BM/PB samples from 55 NT and 19 RE patients, highlight the differences
between biological specimens suggesting that for RE patients, PB is less reli-
able than BM.
A B
C
mutation quantification. Of note, 2 samples scored WT in
all three compartments (Figure 4 and Online Supplementary
Figure S6), while in 3 other patients MYD88L265P was
detected in BM and PB, but scored WT in plasma ctDNA;
these samples were excluded from the analysis since neg-
ativity, confirmed by RNAseP analysis, was ascribed to
pre-analytical issues, related to sample collection and stor-
age. Two cases were erroneously collected in lithium-
heparin tubes instead of K3EDTA, while one case was col-
lected correctly but processed more than 6 h after the
blood had been drawn, confirming the importance of col-
lection tubes and processing timing for good quality
ctDNA, as already reported.33–35
Minimal residual disease monitoring in Waldenström
macroglobulinemia by MYD88L265P droplet digital
polymerase chain reaction 
To explore the potential role of MYD88L265P mutation
detection by ddPCR for MRD monitoring and therapy
response evaluation, we focused our analysis on 52
patients who had at least one available follow-up sample.
These patients’ features and the treatment they received
are pre-
sented in
O n l i n e
MYD88L265P mutation detection by ddPCR on BM, PB and ctDNA
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Figure 3. MYD88L265P assay and IGH-based approaches are superimposable.
Comparison of MYD88 and IGH-based minimal residual disease monitoring
(expressed as copies of mutation in 1x105 cells) in 23 samples from 10 patients
shows a good degree of correlation (r2=0.64). 
Figure 4. Cell tumor DNA from plasma mirrors the bone
marrow mutation level. MYD88L265P mutated/wild-type
(MUT/WT) ratio in bone marrow (BM), peripheral blood (PB)
and plasma (PL) paired samples from 32 patients show no
statistical differences between BM and PL. The dashed red
line shows the cut-off for mutational status. Symbols below
the red line represent MYD88WT samples. RE: relapsed; NT:
Naïve-to-Treatment patients.
Figure 2. Digital droplet polymerase chain reaction sensitivity test and exam-
ple plots of controls (MUT vs. WT). (A) ddPCR assay measured on a 10-fold dilu-
tion standard curve, shows a sensitivity of 0.0035% MUT (1 mutated copy in
30000 WT). (B) Example of ddPCR result plot for the MYD88L265P control. (C)
Example of ddPCR result plot for the MYD88WT control. MUT: mutated; WT: wild-
type.
A
B
C
Supplementary Table S4. MRD monitoring of this series is
graphically depicted in Figure 5. All the treatment-naïve
patients were MYD88L265P mutated at baseline (either on
BM or PB or both), while 2 relapsed patients (one BM and
one PB) scored WT (as false negative results, due to pre-
vious rituximab exposure, see below). After therapy, 6/22
informative cases showed MRD negativization on BM
(27%) and 17/35 (49%) on PB, further suggesting a faster
clearance of MRD from PB than from BM. At subsequent
time points, the majority of patients remained MRD-pos-
itive (namely, patients 26, 28-31 and 33-35), some
remained MRD-negative (patients 14-16, 37, 46 and 48),
while a few show alternating results (patients 32, 40 and
50). Given the limited series of patients and the retrospec-
tive nature of the analysis, it is difficult to draw conclu-
sions on the efficacy of single therapeutic schedules in
clearing MRD in WM. However, the high potential of
MRD shrinkage of regimens containing either fludarabine
or bendamustine (each combined with rituximab) is high-
lighted in the Online Supplementary Methods (Online
Supplementary Figure S7A-C). 
Of note, there were 2 false-negative cases among
relapsed patients in this series. Patient 44, who had a base-
line BM sample depicted as WT (meaning “MRD nega-
tive”), but with a borderline mutated:WT ratio, followed
by PB positivity in the first follow-up sample (taken after
3 years). The other false-negative case was patient 45,
whose PB relapsed sample was negative at baseline, but
then reverted to positive during the subsequent follow up
(“MRD reappearance”).
Additionally, 27 paired PB/plasma follow-up samples
highlight the role that ctDNA might have for MYD88L265P
mutation detection in pre-treated cases, as well as for
MRD monitoring. Of note, 14/27 were concordantly pos-
itive and 3/27 concordantly negative, while 9/27 scored
positive only in plasma and 1/27 positive on PB but not on
plasma. Interestingly, the 9 plasma positive cases “res-
cued” by ctDNA analysis showed MYD88L265P levels in
plasma comparable to those detected in paired BM sam-
ples (see Figure 5: patients 52, 50 and 37).
Discussion
ASqPCR has been widely used for MYD88L265P detection
in WM, providing a higher level of sensitivity than Sanger
sequencing.6,21 However, the recently developed ddPCR
simplifies and improves the accuracy of MRD monitor-
ing.24,31
This study describes a new ddPCR tool for MYD88L265P
screening and MRD monitoring in WM. Our results can
be summarized as follows:
1. ddPCR is a sensitive tool for MYD88L265P detection in
WM and provides higher resolution compared to the
canonical ASqPCR;
2. MYD88L265P ddPCR assay is particularly useful for reli-
D. Drandi et al.
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Figure 5. MYD88L265P can be used for disease monitoring. MYD88L265P monitored in 52 patients with at least one follow-up (FU) sample. ctDNA: cell tumor DNA; RE:
relapsed at baseline; NT: Naïve to Treatment at baseline; MRD: minimal residual disease; PL: plasma; BM: bone marrow; PB: peripheral blood.
able screening of low infiltrated WM specimens, such as
unsorted BM or PB (routinely used in clinical practice);
3. both BM and PB are informative in treatment-naïve
patients when tested for MYD88L265P by ddPCR; however,
in relapsed patients (mainly exposed to rituximab), PB has
a 1 log lower median mutated:WT ratio compared to BM,
likely related to the efficacy of the anti-CD20 antibody in
clearing the circulating tumor cells: therefore, BM analysis
should be preferred for these patients;
4. the MYD88L265P ddPCR assay can be reliably used for
MRD purposes, being as informative as the classical, stan-
dardized but less applicable, IGH-based MRD assay, not
yet validated in WM; 
5. the MYD88L265P ddPCR assay targeting ctDNA is very
promising for identifying the mutation in less invasively
collected tissues, such as plasma or urine, and in samples
from pre-treated patients.
The here described MYD88L265P ddPCR assay showed an
overall mutation detection rate on baseline unselected
mononuclear cells samples of 95.3% in BM and 71.2% in
PB. These data might help to solve the still open debate
on whether to use sorted versus unsorted BM mononu-
clear cells to assess the MYD88L265P mutation36 and to
extend the implementation of the ddPCR mutation assay
to general diagnostic laboratories that do not routinely
perform cell selection. At present, only 40% of
MYD88L265P cases can be detected by ASqPCR using unse-
lected PB cells, with an overall sensitivity of 39.5% and
specificity of 100%.37
In our study we observed that the ddPCR assay on uns-
elected cells greatly improved the rate of MYD88L265P
detection compared to that achieved by ASqPCR. In fact,
an analysis of 74 paired BM/PB baseline samples showed
an overall detection rate of 93% (69/74) in BM and 72%
(53/74) in PB. Among 69 patients with detectable muta-
tions in BM samples, the sensitivity for MYD88L265P muta-
tion detection by ddPCR on paired PB samples was 77%
(53/69). The highly sensitive results of MYD88L265P ddPCR
assay on unsorted samples makes this assay ideal for
diagnostic use in clinical routine, avoiding the costs and
technical requirements of cell sorting. In addition, our
data confirmed, as also reported by Xu et al.,37 that PB
samples are suboptimal for mutational screening in previ-
ously treated patients, evidence confirmed by the high
rate of false-negative results. The sensitivity of our assay
in PB samples dropped from 85% in treatment-naïve
patients to 47% in relapsed patients. Thus, a BM sample
is essential to accurately identify MYD88L265P WT status in
pre-treated patients (strongly suggested, for example,
before starting an expensive therapy with ibrutinib). 
This study shows that, besides its potential diagnostic
role, MYD88L265P can effectively and easily be used for MRD
monitoring in WM, achieving similar results to the less-
applicable IGH-based MRD assay. In fact, monitoring allele
levels can also provide insights into treatment effectiveness
in a disease whose therapeutic scenario is rapidly changing,
with many new and highly effective drugs.13 Of note, a
report claimed the achievement of the first “molecular
remission” in WM treated with carfilzomib.38 However, the
deepness of molecular response matters, as does the sensi-
tivity of the assay used for MYD88L265P detection, which was
quite modest in that case (1.00x10-3)6 compared to the
newly developed flow cytometry assays39 and with the
ddPCR strategy described in this manuscript. 
We observed that the agreement between ddPCR and
ASqPCR results was weaker in follow-up samples than in
baseline ones. Further evaluations on large, prospective
series of patients are needed to assess whether ddPCR
could be useful for the identification of false-positive
ASqPCR results, as was recently demonstrated in a next-
generation sequencing/real-time quantitative PCR com-
parison performed in acute lymphoblastic leukemia.40
Moreover, a methodological validation against IGH-
based MRD detection and multiparametric flow cytome-
try, as well as correlations with clinical impact, are eager-
ly awaited in this setting and are currently ongoing in
series of external samples. 
The most innovative aspect of our study is the impact
that ctDNA might have on MYD88L265P mutation detec-
tion and MRD monitoring. We showed that ctDNA mir-
rors the BM mutational burden much better than gDNA
from PB at baseline. Moreover, our data suggest that
ctDNA might be able to reflect the dynamic changes in
tumor burden in response to treatment, with higher sen-
sitivity than PB, which is particularly promising in pre-
treated cases (Figures 3 and 4). Similar promising data
have been obtained with ctDNA extracted from exo-
somes from plasma and urine in a pivotal series of
patients (D Drandi et al., 2018, unpublished data),
although further investigations, as well as technical opti-
mization, are needed. Nevertheless, these data add to the
previously published experiences on the promising role of
ctDNA analysis in lymphoproliferative disorders other
than WM.41–50 Indeed, ctDNA represents an alternative,
less invasive and “patient-friendly” tissue source for
mutational analysis, and eventually MRD, which is espe-
cially attractive for screening and monitoring asympto-
matic patients, such as those with MGUS. (MYD88L265P
ddPCR screening on a large group of IgM-MGUS patients
is currently ongoing). However, plasma collection needs
particular care since blood collection tubes and drawing
procedures, as well known, can affect the stability of
ctDNA.33,34 Pre-analytical standardized procedures are a
prerequisite for clinical application and for consolidation
of the promising potential of ctDNA analysis.
Finally, we described the impact of different therapies
on MRD clearance in WM (i.e. chlorambucil, rituximab
monotherapy), RCD (rituximab, cyclophosphamide,
dexamethasone), FCR (fludarabine, cyclophosphamide,
rituximab) and bendamustine-containing regimens
(Online Supplementary Appendix). We acknowledge that
the limitations of the present study include the compos-
ite and retrospective nature of the series of patients
characterized, moreover, by little outcome information.
One of the main goals of this manuscript was the tech-
nical description of the MYD88L265P ddPCR assay on
unsorted cells. The illustration of the broad range of
possible applications, including those on liquid biopsy,
makes this approach potentially practical for implemen-
tation in routine diagnostic laboratories. We are aware
that this assay represents exploratory research, whose
real advantages and predictive values need to be further
validated in the context of prospective clinical trials. For
this purpose, we are currently investigating  MRD
assessment by ddPCR on gDNA and ctDNA in the con-
text of a phase II prospective study of relapsed WM
patients, sponsored by the Fondazione Italiana Linfomi
(EudraCT number: 2013-005129-22). Moreover, further
efforts to establish uniform guidelines regarding stan-
dardization procedures for sample collection and
MYD88L265P mutation detection by ddPCR on BM, PB and ctDNA
haematologica | 2018; 103(6) 1035
methodological validation are currently ongoing, both at
national and European levels. 
In conclusion, our study shows that ddPCR is a feasible
and highly sensitive assay for MYD88L265P mutational
screening and MRD monitoring in WM, particularly in
samples harboring low concentrations of circulating
tumor cells. For this reason, plasma ctDNA represents a
promising tissue source, and might be an attractive, less
invasive alternative to BM for MYD88L265P detection, also
beyond the scenario of WM. 
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